Interestingly, SU-based compounds (such as glimepiride) have been observed to uncouple the glucose dependence of GLP-1R agonists and promote increased rates of hypoglycaemia in patients using GLP-1R agonists together with SU (Table 1) [17,19,43–45]. Here, GLP1R is linked to Hypoglycemia.